long time holding has caused nothing but frustration.

small cap, large growth

drug stock that took big hit...destined to go back up upon approval from FDA

Gamble. Looking to double up on price with approval of migraine drug.

Counting on slow rise back to low
teens

Pozen (POZN) was downgraded to Hold rating from Buy at Jefferies. Price target drops to $10 from $20, and FY 2009 eps estimates dip to ($0.76) from $0.53

From Barron's 7-16-07:

"Migraines, according to the National Library of Medicine, can be triggered by bright lights, loud noises, weather changes, smoke, perfumes, alcohol, caffeine, red wine, aged cheese, smoked fish, bacon, chocolates, nuts, avocado, bananas, onions ...you get the idea. Over the past year, 18% of U.S. women and 6% of men have suffered at least one attack.

So it's easy to see why shares of a little-known drug-development company, Pozen (POZN), have run up 16% since June. Pozen has developed with GlaxoSmithKline (GSK) a tablet for treating migraines, and a regulatory decision regarding the remedy, known as Trexima, is expected Aug. 1.

Option prices suggest that the market sees a 60% chance Trexima will be approved by the Food and Drug Administration, but Citigroup analyst Lucy Lu is more optimistic. She pegs the odds of an FDA nod at 80%, given Trexima's superior efficacy results in clinical trials and a safety profile comparable to Imitrex, currently the go-to drug with 55% of the U.S. market. Imitrex already is a winner for GlaxoSmithKline.

Lu believes a yes could drive Pozen shares, trading at 18.50 recently, to between 23 and 25 and towards her 12-month target of 28. "We believe Trexima will be the new gold standard treatment of migraine headaches," she notes."

immetrex approval

Too good to enumerate

Blockbuster (anticipated yearly sales of more than 1 Billion) Drug Candidates:


1. Trexima for migraines...August FDA decision. The analysts are expecting approval. Glaxo-Smith-Klein is the developmental/commercialization partner.
PN 400 Arthritis medicine...Phase 3 trials to start this year. Astra Zeneca (375 million contract) is the developmental/commercialization partner.
PA 325 Safer (in terms of gastrointestinal damage) Aspirin. Stellar results from the first study were released on March 6th.

No business plan here... combine generic drugs and try to resell them at a premium. Insurance companies and the VA will simply not pay for it.